Returning by huge demand, the hotly anticipated 2nd Gene Therapy Potency Summit will help you to navigate matrix approaches for potency, elucidate the mechanism of action for complex gene therapies, and consistently measure biological activity to demonstrate product efficacy to regulators.

Overcome the unique and diverse challenges that potency poses for gene therapies with novel case studies and unpublished data on developing phase-appropriate assays, cutting-edge HPLC and mass spectrometry approaches, and parallel line analysis.

We engaged with industry leaders from clinically successful companies to develop your own potency strategy, with collaborative sessions addressing the latest FDA guidance, partnering and resource management with CROs, and balancing risk in upfront strategy.

With industry-leading experts uniting 70+ potency assay developers and solution providers from the likes of Sarepta Therapeutics, Ultragenyx, Sanofi, Spark Therapeutics, Vertex, Sangamo Therapeutics, and many others, this meeting offered the most comprehensive agenda yet.

Delegates joined us July to collaborate with critical decision makers, perfect their potency strategy, and ultimately demonstrate to regulators that their product was efficacious.